-
New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented at WCLC 2020Daiichi Sankyo2021-02-02 11:10:14New Biomarker Analyses from Patritumab Deruxtecan Phase 1 Study in Patients with EGFR-Mutated NSCLC Presented
-
Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small Cell Lung CancerDaiichi Sankyo2021-02-02 11:32:38Datopotamab Deruxtecan and ENHERTU Show Promising Early Clinical Activity in Patients with Advanced Non-Small
-
ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics SocietyDaiichi Sankyo2021-02-02 11:32:52ENHERTU® Receives Prime Minister’s Award from the Japan Techno-Economics Society
-
ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast CancerDaiichi Sankyo2021-02-02 11:33:01ENHERTU® Approved in the EU for the Treatment of HER2 Positive Metastatic Breast Cancer
-
New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung CancerDaiichi Sankyo2021-02-02 11:33:08New Research Data Across DXd ADC Portfolio at WCLC Showcases Daiichi Sankyo’s Continued Commitment in Lung
-
First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with ezetimibe NUSTENDI® ▼ (bempedoic acid and ezetimibe) tablet approved in SwitzerlandDaiichi Sankyo2021-02-02 11:33:17First-in-class cholesterol-lowering treatment NILEMDO® ▼ (bempedoic acid) tablet and its combination with
-
TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC with Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:35:37TROPION-Lung05 Phase 2 Trial of Datopotamab Deruxtecan Initiated in Patients with Advanced or Metastatic NSCLC
-
TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in Previously Treated Patients with Advanced or Metastatic NSCLC Without Actionable Genomic AlterationsDaiichi Sankyo2020-12-14 15:36:13TROPION-Lung01 Head-to-Head Phase 3 Trial Initiated to Evaluate Datopotamab Deruxtecan Versus Docetaxel in
-
Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast CancerDaiichi Sankyo2020-12-14 14:49:29Trastuzumab Deruxtecan Recommended for Approval in the EU by CHMP for HER2 Positive Metastatic Breast Cancer
-
Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2 Expressing Metastatic Breast Cancer Presented at the 2020 San Antonio Breast Cancer SymposiumDaiichi Sankyo2023-11-10 06:53:58Results from First Combination Trial of ENHERTU® and Immune Checkpoint Inhibitor in Patients with HER2
